Nexthera Capital’s Stemline Therapeutics, Inc. STML Stock Holding History

Nexthera Capital’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-325,526	Closed	-$4.18M	–	35
2019 Q1	$4.18M	Sell	325,526 -386,032	-54%	-$4.36M	5.08%	8
2018 Q4	$6.76M	Buy	711,558 +129,488	+22%	+$1.68M	2.79%	12
2018 Q3	$9.66M	Buy	582,070 +22,553	+4%	+$362K	1.85%	17
2018 Q2	$8.98M	Buy	559,517 +35,893	+7%	+$641K	1.39%	22
2018 Q1	$8.01M	Buy	+523,624	New	+$8.16M	1.32%	25

Other funds holding STML

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Nexthera Capital's STML Position: Q2 2019 in Review

Nexthera Capital sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 325,526 shares — an estimated $4.18M sold.

Nexthera Capital first reported a position in STML in Q1 2018 and held it in 5 quarters. The position peaked at $9.66M in Q3 2018. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

Nexthera Capital reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Nexthera Capital sold 325,526 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $4.18M.
Nexthera Capital first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
Nexthera Capital's Stemline Therapeutics, Inc. position peaked at $9.66M in Q3 2018.
96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.